HLB's extraordinary shareholders' meeting has approved the company’s transfer listing from the tech-heavy Kosdaq to the main bourse Kospi market.

In a public filing Thursday, HLB said that the agenda, "The proposal to abolish the conditional listing on the Kosdaq market and transfer listing in the securities market," passed its extra shareholders’ meeting. Earlier, HLB said it was pursuing a transfer listing to the Kospi market at its shareholders’ request.

Following the approval of the listing proposal, HLB will proceed with the transfer listing process by submitting a delisting application to the Kosdaq market and a preliminary examination request to the securities market. Korea Investment & Securities will handle the preliminary listing process as the lead brokerage.

The company expects the delisting process to take about six months.

HLB talked with its shareholders after the extraordinary general meeting. HLB Group Chairman Jin Yang-gon attended the meeting and explained pending business issues.

"The company has been focusing all its energy on winning approval and rapid launch of new drugs in the U.S. market, which accounts for 75 percent of the global liver cancer market," Chairman Jin said. "After the approval of rivoceranib for liver cancer, we will quickly expand the pipeline to other therapeutic areas, such as 'preoperative adjuvant therapy for liver cancer,' to increase corporate value in the long term."